NCT02372240 is a Phase 1, PHASE2 clinical trial of VLX1570 and dexamethasone in Multiple Myeloma, sponsored by Vivolux AB.

Who is sponsoring NCT02372240?

NCT02372240 is sponsored by Vivolux AB.

What drugs are being tested in NCT02372240?

Interventions in NCT02372240: VLX1570 and dexamethasone.

What condition does NCT02372240 study?

NCT02372240 studies Multiple Myeloma.

Is NCT02372240 still recruiting?

NCT02372240 is currently terminated. Last updated 11 May 2018.

Last reviewed 2018-05-11 · How we verify

NCT02372240

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of VLX1570 and Dexamethasone in Myeloma Patients

Terminated Phase 1, PHASE2 Last updated 11 May 2018

What this trial tests

Phase 1, PHASE2 trial testing VLX1570 and dexamethasone in Multiple Myeloma in 15 participants. Terminated before completion.

Timeline

8 April 2015

Primary endpoint
24 May 2017

24 May 2017

Quick facts

Lead sponsor	Vivolux AB
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	8 April 2015
Primary completion	24 May 2017
Estimated completion	24 May 2017
Sites	1 location across United States

Drugs / interventions tested

VLX1570 and dexamethasone — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Vivolux AB — full company profile →

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1/2 single arm study to determine the safety and efficacy of VLX1570 IV infusion administered with low dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

An expanded lexicon for the ubiquitin code.
Dikic I, Schulman BA. · · 2023 · cited 318× · PMID 36284179 · DOI 10.1038/s41580-022-00543-1
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.
Liu F, Chen J, Li K, Li H, et al · · 2024 · cited 195× · PMID 39048965 · DOI 10.1186/s12943-024-02046-3
Small Molecule NF-κB Pathway Inhibitors in Clinic.
Ramadass V, Vaiyapuri T, Tergaonkar V. · · 2020 · cited 154× · PMID 32708302 · DOI 10.3390/ijms21145164
Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion.
Harris IS, Endress JE, Coloff JL, Selfors LM, et al · · 2019 · cited 138× · PMID 30799286 · DOI 10.1016/j.cmet.2019.01.020
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Wang X, Mazurkiewicz M, Hillert EK, Olofsson MH, et al · · 2016 · cited 124× · PMID 27264969 · DOI 10.1038/srep26979
Regulation of Wnt Signaling through Ubiquitination and Deubiquitination in Cancers.
Park HB, Kim JW, Baek KH. · · 2020 · cited 112× · PMID 32486158 · DOI 10.3390/ijms21113904
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Rowinsky EK, Paner A, Berdeja JG, Paba-Prada C, et al · · 2020 · cited 86× · PMID 32125598 · DOI 10.1007/s10637-020-00915-4
Activity-based probes for the ubiquitin conjugation-deconjugation machinery: new chemistries, new tools, and new insights.
Hewings DS, Flygare JA, Bogyo M, Wertz IE. · · 2017 · cited 85× · PMID 28196299 · DOI 10.1111/febs.14039

Verify or expand the search:

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Vivolux AB trials

Trials by the same sponsor.

NCT02222363 — Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02372240 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vivolux AB
Last refreshed: 11 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02372240.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing